Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
A staggering 65% of the TB cases in India are in the 15-45 age group
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
The expansion makes Exothera one of the largest viral vector facilities in Europe
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Subscribe To Our Newsletter & Stay Updated
